In this open-label , randomized , phase @ study , patients with EGFR wild-type and EGFR FISH-positive adenocarcinoma who had developed disease progression after @ prior platinum-based chemotherapy were randomly assigned ( @:@ ) to receive erlotinib or pemetrexed until the time of disease progression or death , unacceptable toxicity , or a request for discontinuation by the patient .